MarketPulse
N

$NKTR

53 articles found
2 positive
51 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Nektar Therapeutics Hit With Securities Class Action Over Failed Trial Disclosures

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.
NKTRsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Eos Energy Investors Face May 2026 Deadline in Securities Class Action

Rosen Law Firm pursues class action against Eos Energy Enterprises for alleged false statements about operations and guidance. Investors must act by May 5, 2026 deadline.
SMREOSENKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Lawsuits Target Nektar, Enphase Over Alleged False Statements

Rosen Law Firm files securities class actions against Nektar Therapeutics, Enphase Energy, and Aquestive Therapeutics. Investors have until May 5, 2026 to join.
ENPHAQSTNKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Enphase Energy Faces Securities Lawsuit Over Inventory, Credit Termination Claims

Rosen Law Firm filed securities class action against Enphase Energy ($ENPH) alleging false statements on inventory and renewable energy credits. Deadline April 20, 2026.
ENPHAQSTNKTRsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Lawsuit Filed Against Aquestive Therapeutics Over Alleged Securities Violations

Rosen Law Firm filed class action against Aquestive Therapeutics alleging false statements about product development and regulatory matters. Eligible investors should act before deadline.
ENPHAQSTNKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nektar Therapeutics Faces Class Action Over Misleading Trial Data Claims

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial enrollment protocols, potentially harming investor value.
NKTRsecurities fraudclass action lawsuit
BenzingaBenzinga··Business Wire

Nektar Therapeutics Faces Securities Fraud Investigation After Failed Trial Announcement

Law firm investigates $NKTR over December trial failure disclosure. Stock dropped 7.8% after alopecia areata Phase 2b study missed endpoints due to ineligible patients.
NKTRshareholder lawsuitstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Nektar Therapeutics Faces Securities Class Action Over Failed Trial Disclosure

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.
NKTRclass actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bernstein Liebhard Llp

Nektar Therapeutics Faces Securities Class Action Over Failed Trial Disclosures

Law firm Bernstein Liebhard announces class action against $NKTR over alleged misrepresentations regarding Phase 2b trial results, affecting investors from February to December 2025.
PLUGSLNONKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Nektar Therapeutics Faces Securities Class Action Over Alleged Misleading Trial Statements

Rosen Law Firm sues Nektar Therapeutics for alleged false statements about clinical trial protocols, seeking damages for injured investors as litigation moves forward.
EOSESLNONKTRsecurities class actionlead plaintiff
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Nektar Therapeutics Faces Securities Fraud Class Action Over Failed Trial Disclosures

Schall Law Firm launches class action against $NKTR for alleged securities fraud tied to REZOLVE-AA trial protocol violations and misstatements between February-December 2025.
NKTRsecurities fraudclass action lawsuit
BenzingaBenzinga··Djs Law Group

Nektar Therapeutics Faces Class Action Lawsuit Over Misleading REZOLVE-AA Study Claims

Nektar Therapeutics ($NKTR) faces class action lawsuit alleging false statements about REZOLVE-AA trial protocol adherence, threatening regulatory approval timelines and shareholder value.
NKTRclass action lawsuitfalse statements
BenzingaBenzinga··Business Wire

Nektar Therapeutics Faces Securities Fraud Lawsuit Over Misleading Trial Claims

Schall Law Firm seeks investors in class action against $NKTR over alleged false statements regarding REZOLVE-AA trial enrollment and integrity.
NKTRsecurities fraudclass action lawsuit